AppointmentsBavarian Nordic names new CEO; Abivax and ProQR add key leadersEvery Friday, The Leadership Edit looks at the people taking new roles across European biotech and what their moves may tell us about the companies they join. We’ll follow chief executives, scientific … more ➔
licensingRoche signs two deals worth about $3.5B in one dayRoche signed two research partnerships on Sept. 24: one with Atavistik Bio to discover drugs for cardiovascular, renal and metabolic diseases, and another with Earendil Labs to develop cancer antibodies. … more ➔
innovation policyNine pharma companies urge Europe to invest more in medicinesEuropean biotech and clinical-research figures broadly agree with nine major drugmakers whose chairs signed a letter urging governments to reward new medicines better, but say the fixes go well beyond … more ➔
startupsKasvu raises €30M for depression drug targeting TrkBFinnish biotech Kasvu Therapeutics has raised €30 million in Series A financing to take its lead depression candidate into clinical development, adding to a growing number of European investments in … more ➔
licensingBoehringer pays up to $250M to expand Variant Bio’s pact into heart diseaseBoehringer Ingelheim has expanded its partnership with Variant Bio into cardiovascular disease, adding potential payments exceeding $250 million (€219 million). The agreement builds on a kidney disease … more ➔
fundraisingBasecamp Research raises $140M for AI-designed cell therapiesLondon-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic. … more ➔
fundraisingViferaXS secures up to €12M for leukemia trialGerman biotech ViferaXS has closed a Series A financing of up to €12 million, including grant funding, to advance its peptide-based cancer immunotherapy into a randomized Phase 2 trial in chronic lymphocytic … more ➔
financingScarlet gets $14M for smart red blood cellsUK biotech Scarlet Therapeutics will lead a consortium developing red blood cells that can sense physiological changes and respond to them under a U.S. Defense Advanced Research Projects Agency (DARPA) … more ➔
clinical dataRoche hits Phase 3 IgAN endpoint but holds back dataRoche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped short of disclosing the size of the effect. more ➔
drug deliveryCell therapies: breaking barriers in solid tumoursIt’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable therapy against tumours. But when it comes to fighting solid tumours, … more ➔
